Minor delay to Evaxion (NASDAQ: EVAX) 2025 annual report and call

Rhea-AI Filing Summary

Evaxion A/S reported a slight delay in filing and publishing its 2025 annual report because of unforeseen technical issues at external vendors related to regulatory filing requirements. The report itself has been finalized and will be filed and published as soon as the technical problems are resolved.

As a result of this delay, the conference call and webcast planned for today have been moved to Friday, March 6 at 8.30 ET / 14.30 CET. Evaxion is a clinical-stage TechBio company that uses its AI-Immunology™ platform to develop novel vaccine candidates for cancer and infectious diseases.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On March 5, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion plans to file 2025 annual report later today". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion plans to file 2025 annual report later today

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: March 5, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Evaxion plans to file 2025 annual report later today

COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.  

The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself. 

As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 ET/14.30 CET.   

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event. 

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event. 

Contact information  

Evaxion A/S 
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai 

About Evaxion  

Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. 

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development 

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.  

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.  

Forward-looking statement  

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.  

FAQ

What did Evaxion A/S (EVAX) announce in its March 2026 Form 6-K?

Evaxion announced a slight delay in filing its 2025 annual report due to technical issues with external vendors. The report is finalized and will be filed and published as soon as possible, and the associated results conference call has been rescheduled by one day.

Why is Evaxion (EVAX) delaying its 2025 annual report filing?

The 2025 annual report filing is delayed because of unforeseen technical issues with external vendors tied to regulatory filing demands. Evaxion states the report itself is already finalized, and the problems do not relate to its content, only to the submission process.

When will Evaxion’s rescheduled 2025 annual report conference call take place?

The conference call and webcast are rescheduled to Friday, March 6 at 8.30 ET / 14.30 CET. Participants are asked to register in advance via the provided link to receive dial-in numbers and a unique PIN, with access opening 15 minutes before the event.

Do the technical issues affect the content of Evaxion’s 2025 annual report?

Evaxion states that the technical issues do not affect the report itself, only the filing process. The company explains the 2025 annual report has been finalized as planned and that the issues stem from regulatory filing demands handled by external vendors.

How can investors access Evaxion’s 2025 annual report webcast and Q&A?

Investors can join the webcast through a dedicated online link and may access the conference call by registering in advance to obtain dial-in details and a unique PIN. A recording of the webcast will be available on Evaxion’s website shortly after the live event.

What kind of company is Evaxion A/S (EVAX) and what does it develop?

Evaxion is a clinical-stage TechBio company built on its AI-Immunology™ platform, which uses artificial intelligence to decode the immune system. It develops personalized and off-the-shelf cancer vaccine candidates and prophylactic vaccines for infectious diseases, targeting high unmet medical needs globally.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.7 KB